Objectives While pembrolizumab improves overall survival (OS) in a subset of advanced
nonsmall cell lung cancer (aNSCLC) patients (pts) in clinical trials, individuals with poor …

Background In clinical trials, first-line treatment with pembrolizumab improved overall
survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a …

Objectives As first line therapy, pembrolizumab provides longer progression free survival
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …

Background Patients with non–small cell lung cancer (NSCLC) and a poor Eastern
Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from …

Background In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1)
expression on≥ 50% of tumor cells, first-line treatment with the PD-1 inhibitor …

Background Pembrolizumab is the first-line standard of care for advanced non–small cell
lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS)≥ 50%. Eastern …

Background This study aimed to comprehensively review the available evidence regarding
the efficacy of first-line pembrolizumab for advanced/metastatic non–small-cell lung cancer …

Lung cancer is the leading killer of both men and women in the US, and the 5-year survival
remains poor. However, the approval of checkpoint blockade immunotherapy has shifted the …

Background Several randomized controlled trials (RCTs) have confirmed the favorable
clinical benefit of pembrolizumab in advanced non-small cell lung cancer (NSCLC) …

Lung cancer is one of the most frequently diagnosed cancers in the world with more than 2
million new cases diagnosed every year. 1 As the largest developing country worldwide …